AKBA Akebia Therapeutics, Inc.: institutional ownership and insider trading
180 funds reported holding $161M of Akebia Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $7.11M, with 36 new positions and 36 funds selling out; over the last 12 months insiders bought $86.6K and sold $963K on the open market; over its last four quarters it reported revenue of $219M and net income of −$29.6M.
AKBA revenue and earnings
- Quarter ended Jun 30, 2026: revenue $49.1M, net income −$8.91M, EPS -0.03
- Quarter ended Mar 31, 2026: revenue $53.5M, net income −$9.05M, EPS -0.03
- Quarter ended Dec 31, 2025: revenue $57.6M, net income −$12.2M, EPS -0.05
- Quarter ended Sep 30, 2025: revenue $58.8M, net income $540K, EPS 0.00
Famous investors holding AKBA
- Izzy Englander (Millennium Management): $3.64M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $2.78M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $2.26M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $1.40M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $100K, 0.0% of the portfolio
Largest institutional holders of AKBA
- VANGUARD GROUP INC — $25.8M
- BlackRock, Inc. (BLK) — $22.8M
- VANGUARD CAPITAL MANAGEMENT LLC — $12.9M
- Alerce Investment Management, L.P. — $10.9M
- AQR CAPITAL MANAGEMENT LLC — $10.4M
- GEODE CAPITAL MANAGEMENT, LLC — $7.67M
- STATE STREET CORP (STT, STT-PG) — $6.15M
- JACOBS LEVY EQUITY MANAGEMENT, INC — $4.87M
- ACADIAN ASSET MANAGEMENT LLC — $4.56M
- GOLDMAN SACHS GROUP INC (GS, GSCE, GS-PA, GS-PC, GS-PD) — $4.21M
Recent AKBA insider trades
- Jun 29, 2026: Ostrowski Erik sold 56,019 shares ($62.2K)
- Mar 4, 2026: Butler John P. bought 69,270 shares ($86.6K)
- Feb 2, 2026: Butler John P. sold 341,305 shares ($474K)
- Feb 2, 2026: Burke Steven Keith sold 67,658 shares ($94.0K)
5%+ owners
- BlackRock, Inc.: 7.2% (Schedule 13G/A, filed Jan 21, 2026)
Who owns the most AKBA stock?
The largest institutional holders of Akebia Therapeutics, Inc. in the latest 13F filings are VANGUARD GROUP INC ($25.8M), BlackRock, Inc. (BLK) ($22.8M), VANGUARD CAPITAL MANAGEMENT LLC ($12.9M).
Are insiders buying or selling AKBA?
Over the last 12 months insiders bought $86.6K and sold $963K of Akebia Therapeutics, Inc. stock on the open market (SEC Form 4).
Which famous investors own AKBA?
Izzy Englander, Two Sigma, Ken Griffin, Renaissance Technologies, D. E. Shaw.
What was AKBA's revenue last quarter?
Akebia Therapeutics, Inc. reported revenue of $49.1M for the quarter ended June 30, 2026, with net income of −$8.91M.
Which ETFs hold AKBA?
1 ETFs and mutual funds hold it among their top 100 positions, including SBIO.